This educational activity is supported by educational grants from the following companies:
Celgene Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Management of Newly Diagnosed Multiple Myeloma Patients
Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
The University of Arizona Cancer Center
Multiple myeloma is a complex, multifarious disease. This activity will help the advanced practitioner understand the epidemiology, signs and symptoms, and work-up for newly diagnosed patients, as well as provide new insight into the underlying genomics (molecular and genomic markers) that help in the diagnosis, risk assessment, and staging/classification of multiple myeloma, and how this all impacts an individualized approach to treatment.
Relapsed or Refractory Multiple Myeloma
Management of Multiple Myeloma Patients Treated With Immunotherapy
Adjunctive and Supportive Care in Multiple Myeloma
Risk Stratification in Multiple Myeloma
How do IMIDs work?
What does an advanced practitioner need to know to create an optimal treatment regimen for the individual patient and explain the benefits and risks of the available choice to patients?
Briefly define low-risk vs high risk patient and how risk stratification influences treatment decisions.
What are the toxicities associated with the agents used for multiple myeloma?
What are some monitoring parameters for toxicities to establish?
How can I increase patient adherence to treatment regimens for multiple myeloma?
Bone Marrow Biopsy Demonstration Video